Figure 4.

Cav1 Deletion in MAMs Leads to Increased Metastatic Growth and Angiogenesis

(A) Number of lung metastatic nodules upon tail vein injection of LLC cells. Total mice, n = 6 per genotype.

(B) Tumor cell extravasation measured by qRT-PCR analysis on whole lungs upon tail vein injection of LLC cells. Total mice, n = 4 per condition.

(C–F) FACS quantification of total CD45⁺ leukocytes (C), F4/80⁺ MAMs (D), M2-like CD206⁺ MAMs (E), and MHC class II^low MAMs (F) in WT→WT and Cav1 KO→WT lung metastatic lesions. n = 4 mice per genotype.

(G–I) Number of CD31⁺ blood vessels in LLC metastatic lesions (G) and representative images (H). Scale bar, 50 μm. Number of CD31⁺ blood vessels in primary LLC tumors (I). n = 10 mice per genotype.

(J) Number of CD31⁺ blood vessels in LLC metastatic lesions upon treatment with clodronate liposomes or PBS. n = 9 mice per condition.

(K and L) Number of CD31⁺ blood vessels in lung metastatic lesions of PyMT mice (K) and representative images (L). Scale bar, 50 μm. Total mice, n = 7 per genotype.

(M and N) Number of CD31⁺ blood vessels in E0771 metastatic lesions in the liver (M) and representative images (N). Scale bar, 50 μm. n = 5 mice per genotype.

^∗∗p < 0.01, ^∗∗∗p < 0.001, and ^∗∗∗∗p < 0.0001 versus WT→WT. ^#p < 0.05 versus PBS. ns, not significant. All graphs show mean ± SEM.